DexCom (DXCM) has regained its leadership position in Med-Tech and showing relative strength once again nearing a range breakout of a large weekly bull flag. The range break alone measures to a $575 target while the flag targets even higher. DXCM remains the best-in-class play on Diabetes and also now has litigation ongoing versus Abbott Labs (ABT) for patent infringement. DXCM’s new G7 device is a likely catalyst for growth re-acceleration.